Literature DB >> 10369474

Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists.

J Y Crider1, B W Griffin, N A Sharif.   

Abstract

Various prostaglandin agonists representing various classes of receptor subtypes were evaluated for their ability to stimulate adenylyl cyclase via the endogenous DP receptor in embryonic bovine tracheal (EBTr) cells. Two antagonists were used to block the agonist-induced cyclic AMP production. ZK118182 (EC50 = 16+/-4 nM), RS-93520 (EC50 = 23+/- 4 nM), SQ27986 (EC50 = 33+/-9 nM), ZK110841 (EC50 = 33+/-5 nM), BW245C (EC50 = 59+/-19 nM) and PGD2 (EC50=101+/-10 nM) (n = 4-70) were the most potent agonists. Whilst most compounds were full agonists (Emax = 100% relative to PGD2), BW245C was significantly more efficacious than PGD2 (Emax = 121+/-3%; P<0.001) and RS-93520 appeared to be a partial agonist (Emax = 64+/-9%; P<0.001). Agonists from the EP (e.g. enprostil; misoprostol; butaprost), FP (e.g. cloprostenol; fluprostenol; PHXA85), IP (iloprost; PGI2) and TP (U46619) prostanoid receptor classes were weak agonists or inactive in the EBTr cell assay system. The DP-receptor antagonist, BWA868C, showed a competitive antagonist profile with pA2 values of 8.00+/-0.02 and 8.14+/-0.13 in Schild analyses with two structurally different agonists, BW245C and ZK118182, respectively (n = 3). AH6809, another purported DP-receptor antagonist, weakly inhibited PGD2- and ZK 18182-induced cyclic AMP production (K(i)s = 808+/-193 nM and 782+/-178 nM, respectively). The current studies have characterized the DP receptor positively coupled to adenylyl cyclase in EBTr cells using a wide range of agonist and antagonist prostaglandins. These data support the utility of the EBTr cell line as a useful tool for the evaluation of DP receptor agonists and antagonists and for profiling other classes of prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369474      PMCID: PMC1565977          DOI: 10.1038/sj.bjp.0702490

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.

Authors:  M Kiriyama; F Ushikubi; T Kobayashi; M Hirata; Y Sugimoto; S Narumiya
Journal:  Br J Pharmacol       Date:  1997-09       Impact factor: 8.739

2.  The expression of functionally-coupled B2-bradykinin receptors in human corneal epithelial cells and their pharmacological characterization with agonists and antagonists.

Authors:  T K Wiernas; B W Griffin; N A Sharif
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

3.  Partial agonist effects of BW A868C, a selective DP receptor antagonist, on Cl- secretion in dog tracheal epithelium.

Authors:  Y J Liu; D M Jackson; A Blackham; P Leff
Journal:  Eur J Pharmacol       Date:  1996-05-23       Impact factor: 4.432

4.  Pharmacological analysis of mast cell mediator and neurotransmitter receptors coupled to adenylate cyclase and phospholipase C on immunocytochemically-defined human conjunctival epithelial cells.

Authors:  N A Sharif; J Y Crider; B W Griffin; T L Davis; W E Howe
Journal:  J Ocul Pharmacol Ther       Date:  1997-08       Impact factor: 2.671

5.  Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.

Authors:  D H Wright; K M Metters; M Abramovitz; A W Ford-Hutchinson
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

6.  Pharmacological characterization of bradykinin receptors coupled to phosphoinositide turnover in SV40-immortalized human trabecular meshwork cells.

Authors:  N A Sharif; S X Xu
Journal:  Exp Eye Res       Date:  1996-12       Impact factor: 3.467

Review 7.  Initial clinical studies with prostaglandins and their analogues.

Authors:  C B Camras; A Alm
Journal:  Surv Ophthalmol       Date:  1997-02       Impact factor: 6.048

8.  FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study.

Authors:  B W Griffin; G W Williams; J Y Crider; N A Sharif
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

9.  6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist.

Authors:  D F Woodward; D J Pepperl; T H Burkey; J W Regan
Journal:  Biochem Pharmacol       Date:  1995-11-09       Impact factor: 5.858

10.  Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization.

Authors:  B W Griffin; P E Magnino; I H Pang; N A Sharif
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

View more
  12 in total

1.  Prostaglandin D(2), its metabolite 15-d-PGJ(2), and peroxisome proliferator activated receptor-gamma agonists induce apoptosis in transformed, but not normal, human T lineage cells.

Authors:  Sarah G Harris; Richard P Phipps
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

2.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

3.  Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation.

Authors:  Safia Malki; Serge Nef; Cécile Notarnicola; Laurie Thevenet; Stéphan Gasca; Catherine Méjean; Philippe Berta; Francis Poulat; Brigitte Boizet-Bonhoure
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

4.  Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand.

Authors:  N A Sharif; G W Williams; T L Davis
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Excitotoxicity-induced prostaglandin D2 production induces sustained microglial activation and delayed neuronal death.

Authors:  Kensuke Iwasa; Shinji Yamamoto; Sosuke Yagishita; Kei Maruyama; Keisuke Yoshikawa
Journal:  J Lipid Res       Date:  2017-02-07       Impact factor: 5.922

6.  PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury.

Authors:  Sofiyan Saleem; Hean Zhuang; Artur J de Brum-Fernandes; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2007-06-16       Impact factor: 3.386

Review 7.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

8.  Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia.

Authors:  Tatsurou Yagami
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

9.  The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.

Authors:  Subhashini Srinivasan; Fozia Mir; Jin-Sheng Huang; Fadi T Khasawneh; Stephen C-T Lam; Guy C Le Breton
Journal:  J Biol Chem       Date:  2009-04-03       Impact factor: 5.157

10.  Inhibition of interleukin-1beta-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D2.

Authors:  Nadia Zayed; Hassan Afif; Nadir Chabane; Leandra Mfuna-Endam; Mohamed Benderdour; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Rajender K Motiani; Mohamed Trebak; Nicolas Duval; Hassan Fahmi
Journal:  Arthritis Rheum       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.